Breakthroughs for Bleeding: Updates in Treating and Managing Hemophilia
In 1982, the gene encoding factor IX (FIX) was cloned, followed by the cloning of the factor VIII (FVIII) gene in 1984. The events...
Examining Pregnancy Outcomes in Eculizumab-Treated Women With Atypical Hemolytic Uremic Syndrome
Women with atypical hemolytic uremic syndrome (aHUS) treated with eculizumab have similar pregnancy outcomes to women who were not treated with eculizumab, according to...
FDA Approves Ferric Maltol for Treatment of Iron Deficiency
The U.S. Food and Drug Administration (FDA) announced its approval of oral ferric maltol for the treatment of iron deficiency in adults.
Ferric maltol is...
What Does the Future Hold for Gene Therapy in Nonmalignant Hematology?
The human genome contains about 25,000 genes that encode myriad proteins that drive the processes necessary for life. But disruptions, deletions, and mutations can...
Rivipansel Fails to Meet Phase III Trial Endpoints
In a pivotal phase III trial, rivipansel failed to meet its primary and secondary efficacy endpoints in patients with sickle cell disease (SCD) who...
Can ICH Survivors Safely RESTART Antiplatelet Therapy?
While treatment with antiplatelet therapy lessens the risks of subsequent occlusive vascular events, it may increase the risk of recurrent intracerebral hemorrhage (ICH) in...
Roxadustat Improves Hemoglobin Levels and Response Rates in Patients With Anemia Related to Chronic...
According to results from a phase III trial, roxadustat increased hemoglobin levels and hemoglobin response rates, compared with placebo, in patients with anemia and...
Representing Hemostasis and Thrombosis: An Interview With Roy Silverstein, MD
2019 American Society of Hematology (ASH) President Roy Silverstein, MD, speaks about the goals of the ASH Working Group on Hemostasis and Thrombosis.
What is...
Patients With Hemophilia B Report Poor Bleeding Control With Extended Half-Life Factor IX Products
Extended half-life factor IX (FIX) products have been designed to prolong the time between clotting factor injections for patients with hemophilia B, but an...
Two Studies Support Using Concizumab as Prophylaxis in Patients With Hemophilia
Concizumab could be a safe and effective subcutaneous prophylactic treatment option for patients with hemophilia A or B with or without inhibitors, according to...
Current Issue
October 2019, Volume 5, Issue 12
This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.
